J.P. Morgan is raising its price target on Edwards Lifesciences EW from $76 to $78 based upon an impressive 1Q.
In the report, J.P. Morgan writes, “Edwards reported strong 1Q results Wednesday night, with sales of $404.5M (+18.8% reported, +17.1% underlying) coming in $20M above Street consensus and $23M better than our estimate, driven by continued strength from Sapien in Europe, inventory stocking in Critical Care, and an unexpected reacceleration in the base valve business. On the bottom line, 1Q EPS of $0.53 (+32.3%) topped both consensus and our own forecast by a full $0.11. While one-time investment gains contributed $0.024, the company's 1Q operating margin of 19.4% came in an impressive 220bps better than our thinking and, along with the top line upside, drove the majority of the bottom line beat.”
J.P. Morgan maintains an Underweight rating on the stock.
EW closed at $84.36 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsEdwards Lifesciences Corp.Health CareHealth Care EquipmentJ.P. Morgan
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in